entertainment -WSS

entertainment

author：focus 2025-09-27 10:05:52 - browse：7

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Dana Farber says 6 studies to be retracted and 31 corrected

WSS

Harvard's David Sinclair gets blowback over aging

To bolster infectious disease surveillance, genomics powerhouses team up

Mass General, Mayo Clinic look to monetize custom

FDA sets aggressive timeline for overhauling inspection procedures

Medicare drug price lawsuits could be good politics for Biden

TikTok, Instagram influencers need more rules for drug ads

knowledge

entertainment

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

Mass General, Mayo Clinic look to monetize custom

Tori Bowie and the unacceptable rates of Black maternal death

Maisha Meds is a PBM, but don't call it that

Novavax promises a turnaround & Lilly roils the obesity market

He's 19 months old and has one of the world’s rarest diseases

What does generative AI mean for health care? We asked experts

Stem cell biologist probes earliest stages of human development

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Lack of health data on LGBTQ+ people has serious consequences

focus

High breast density mammograms need follow

Families look for replacement for GSK asthma drug Flovent

Streamlined flu vaccines recommended by FDA advisory panel

The public health thinking behind the CDC’s new Covid guidance

Microsoft launches AI tool for clinical documentation through Epic

Future doctors need a strong humanities education

Wikipedia

hotspot

hotspot

focus